News & Updates
Filter by Specialty:
JAK inhibitors ritlecitinib, brepocitinib show promise against alopecia areata
Ritlecitinib and brepocitinib, both Janus kinase (JAK) inhibitors, show promising efficacy for the treatment of alopecia areata (AA), a new trial has found.
JAK inhibitors ritlecitinib, brepocitinib show promise against alopecia areata
23 Dec 2021Ixekizumab effective for difficult-to-treat psoriatic arthritis
The monoclonal antibody ixekizumab improved the signs and symptoms of psoriatic arthritis (PsA) in PsA patients with inadequate response to one or two tumour necrosis factor inhibitors (TNFis), suggests results from a post hoc subanalysis of the SPIRIT-P2 trial.
Ixekizumab effective for difficult-to-treat psoriatic arthritis
08 Dec 2021Tonsillectomy may lower risk of psoriasis
Patients who received tonsillectomy have a lower risk of psoriasis, reports a study, following adjustment for baseline characteristics, comorbidities, and medical confounders relative to a comparison group.
Tonsillectomy may lower risk of psoriasis
27 Nov 2021Hidradenitis suppurativa bidirectionally linked to atopic dermatitis
A recent study has found a two-way association between hidradenitis suppurativa (HS) and atopic dermatitis (AD), warning dermatologists to be aware of this relationship.
Hidradenitis suppurativa bidirectionally linked to atopic dermatitis
27 Nov 2021Patients with vitiligo at risk of hearing loss
A significant association exists between vitiligo and sensorineural hearing loss (SNHL), according to a recent study, which recommends audiologic assessment for early recognition and management of hearing loss in patients with vitiligo.